June 27, 2018 NEWS (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, as well as research and development, signs agreement to work collectively with AATAC to present the “ETST” product line to their vast network of approximately 90,000 retail outlets throughout the U.S.
AATAC will be introducing the Company’s High Grade Full Spectrum Cannabinoids line within its 90,000 outlet reach. The Company has sent AATAC’s operations and distribution teams it’s current batch line to help pave the way to it’s large new batch currently being formulated and packaged. Coupled with the growing consumer interest in the category and positive feedback received from their network, AATAC anticipates a high volume of preorders once an official release date is set.
The Company’s Chief Sales Officer, Jill Buzan stated, “Our association with AATEC which is an advisory board that focuses on convenience stores will give us the opportunity to open up and be available to a market that includes every sector of the population. This could lead to huge exponential growth for ETST’s sales in the next few months.”
Gagan Hunter, the Company’s COO & Director states, “We had some delays finding a new reliable source and manufacturing plant but, it was worth the wait. We found a new manufacture with a better turn around time and a source with a consistent true full spectrum having all the cannabinoids as our previous batch with higher concentration. We strive on providing consistent and reliable source of cannabinoids to our customers. We anticipate on having our new large batch to have enough supply for our rising demand within the next several weeks. Also we are working on a three new chocolate skus and we plan on a new product announcement soon.”
The Company plans on sharing further updates on the new INVENTORY BATCH, RESEARCH & DEVELOPMENT, FORM 10 APPROVAL, and MEDICAL DEVICE updates as they progress.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, and studies through DV Biologics proved it lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets, and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:
Earth Science Pharmaceutical
Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharma, Inc. ("ESP") , which is committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer Dr. Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics
Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
To learn more please visit: www.CannabisThera.com
